214 related articles for article (PubMed ID: 7878192)
21. In vivo effects of a novel thromboxane A2/prostaglandin H2 (TXA2/PGH2) partial agonist, (+)5(Z)-7-[3-endo-phenylsulfonylamino[2.2.1]- bicyclohept-2-exo-yl]-heptenoic acid [(+)-S-145], on vascular, platelet and cardiac function.
Dubé GP; Jakubowski JA; Brune KA; Bemis KG; Kurtz WL
J Pharmacol Exp Ther; 1995 Feb; 272(2):799-807. PubMed ID: 7853197
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
Furci L; Fitzgerald DJ; Fitzgerald GA
J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
[TBL] [Abstract][Full Text] [Related]
23. Interaction of 5-HETE, 12-HETE, 15-HETE and 5,12-diHETE at the human platelet thromboxane A2/prostaglandin H2 receptor.
Mais DE; Saussy DL; Magee DE; Bowling NL
Eicosanoids; 1990; 3(2):121-4. PubMed ID: 2169775
[TBL] [Abstract][Full Text] [Related]
24. Effects of isoprostanes and prostanoids on porcine small intestine.
Unmack MA; Rangachari PK; Skadhauge E
J Pharmacol Exp Ther; 2001 Feb; 296(2):434-41. PubMed ID: 11160628
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
26. Human platelet aggregation and shape change are coupled to separate thromboxane A2-prostaglandin H2 receptors.
Dorn GW; DeJesus A
Am J Physiol; 1991 Feb; 260(2 Pt 2):H327-34. PubMed ID: 1825455
[TBL] [Abstract][Full Text] [Related]
27. Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats.
Rapoport RM; Williams SP
Hypertension; 1996 Jul; 28(1):64-75. PubMed ID: 8675266
[TBL] [Abstract][Full Text] [Related]
28. Platelet endoperoxide/thromboxane A2 (PGH2/TXA2) receptors in patients with myeloproliferative disorders.
Faul C; Renn W; Jaschonek K
Prostaglandins Leukot Essent Fatty Acids; 1991 Aug; 43(4):273-6. PubMed ID: 1835097
[TBL] [Abstract][Full Text] [Related]
29. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor.
Johnson GJ; Dunlop PC; Leis LA; From AH
Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295
[TBL] [Abstract][Full Text] [Related]
30. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.
Halushka PV; Mais DE; Saussy DL
Fed Proc; 1987 Jan; 46(1):149-53. PubMed ID: 2948839
[TBL] [Abstract][Full Text] [Related]
31. Role of endoperoxides in arachidonic acid-induced vasoconstriction in the isolated perfused kidney of the rat.
Quilley J; McGiff JC; Nasjletti A
Br J Pharmacol; 1989 Jan; 96(1):111-6. PubMed ID: 2522332
[TBL] [Abstract][Full Text] [Related]
32. Characterization of prostanoid receptors mediating actions of the isoprostanes, 8-iso-PGE(2) and 8-iso-PGF(2alpha), in some isolated smooth muscle preparations.
Sametz W; Hennerbichler S; Glaser S; Wintersteiger R; Juan H
Br J Pharmacol; 2000 Aug; 130(8):1903-10. PubMed ID: 10952681
[TBL] [Abstract][Full Text] [Related]
33. Glomerular thromboxane A2/prostaglandin H2 receptors: characterization and effect of adriamycin-induced nephrotic syndrome.
Mayeux PR; Shah SV
Biochim Biophys Acta; 1993 Apr; 1181(2):148-54. PubMed ID: 8481403
[TBL] [Abstract][Full Text] [Related]
34. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
Li P; Ferrario CM; Brosnihan KB
J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
[TBL] [Abstract][Full Text] [Related]
35. Polymyxin B increases TXA2/PGH2 agonist and antagonist affinities in human platelet membranes.
Halushka PV; Boehm A; Mais DE
Eicosanoids; 1988; 1(1):41-4. PubMed ID: 2856171
[TBL] [Abstract][Full Text] [Related]
36. Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.
Rosenfeld L; Grover GJ; Stier CT
Cardiovasc Drug Rev; 2001; 19(2):97-115. PubMed ID: 11484065
[TBL] [Abstract][Full Text] [Related]
37. Autacoids mediate coronary vasoconstriction induced by nitric oxide synthesis inhibition.
Pomposiello S; Yang XP; Liu YH; Surakanti M; Rhaleb NE; Sevilla M; Carretero OA
J Cardiovasc Pharmacol; 1997 Nov; 30(5):599-606. PubMed ID: 9388042
[TBL] [Abstract][Full Text] [Related]
38. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets.
Turini ME; Holub BJ
Biochim Biophys Acta; 1994 Jun; 1213(1):21-6. PubMed ID: 8011675
[TBL] [Abstract][Full Text] [Related]
39. Identification of functional PGH2/TxA2 receptors on human endothelial cells.
Kent KC; Collins LJ; Schwerin FT; Raychowdhury MK; Ware JA
Circ Res; 1993 May; 72(5):958-65. PubMed ID: 8477529
[TBL] [Abstract][Full Text] [Related]
40. Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes.
Theis JG; Dellweg H; Perzborn E; Gross R
Biochem Pharmacol; 1992 Aug; 44(3):495-503. PubMed ID: 1387312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
